A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)

Status: Closed to Accrual

Learn more:

• clinicaltrials.gov: #NCT03501381
• News release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.